# PFE Bourla Pushes Turnaround Narrative > Pfizer investor newsletter for May 20–24, 2026. CEO Albert Bourla makes the rounds defending the turnaround narrative as podcasts weigh pipeline progress against patent-cliff exposure. # Pfizer (PFE) Podcast Intelligence Newsletter ### Week of May 20–24, 2026 --- ## This Week's Headline: Bourla Goes Long-Form Pfizer Chairman & CEO **Albert Bourla** sat down with **Nicolai Tangen** (CEO of Norway's $1.7T Sovereign Wealth Fund / NBIM) on **"In Good Company with Nicolai Tangen"**, and it was the *only* substantive Pfizer podcast appearance of the week across 102 episodes scanned. No appearances from Umer Raffat (Evercore), Chris Shibutani (Goldman), Adam Feuerstein (STAT), David Denton (CFO), or Chris Boshoff (CSO). No regulator commentary from Kyle Diamantas or RFK Jr. on Pfizer-specific matters. So this week's signal comes entirely from the **CEO himself**, which means promotional tone, but also unusually direct strategic disclosures. Below is what investors should take away. --- ## 🎙️ Episode: *In Good Company with Nicolai Tangen*, Albert Bourla Interview ### 1. The $50B Revenue Cliff Is (Per Bourla) Behind Them Pfizer's COVID-related revenues collapsed from $56B in 2022 to ~$6B currently, a ~$50B top-line hole. Bourla characterized **2024 and 2025 as "exceptional years"**, top-line growth, beating analyst estimates, and meaningful cost reductions. He acknowledged Pfizer's stock journey from best-performer to worst-performer in 2023. **Investor takeaway:** Bourla is now firmly in the "we've turned the corner" narrative. Watch H2 2026 earnings to validate. ### 2. $80B+ M&A Deployment, Three Bets That Matter Bourla disclosed that Pfizer has deployed **$80+ billion in acquisitions post-COVID**, with three deals accounting for ~80% of spend: | Deal | Thesis | Bourla's May 2026 Update | | --- | --- | --- | | **Seagen** (~$43B) | ADC oncology platform | *"An overwhelming victory. Those products are doing tremendously well."* | | **Medsara** (obesity) | Outbid Novo Nordisk | *"More and more optimistic"*, Phase 2 confirmed **monthly oral dosing** (vs. Lilly/Novo weekly injectables) | | **3S Bio licensing** | Chinese biotech access | Active, but Bourla flagged Chinese licensing as *"not a long-term strategy"* | ### 3. R&D Restructuring, Bourla's Self-Reported Numbers Bourla claimed Pfizer's clinical success rate is now **18–19% vs. industry ~10–11%**, with **Phase 2 success improved from 15–20% historically to 50%+**, and a regulatory approval success rate of **~95%**. He attributed past R&D underperformance to *"focus and governance issues"*, silos between R&D and commercial, and said R&D was restructured into an **end-to-end unified organization in 2025**. *Caveat: These are management-stated metrics, not independently verified.* ### 4. The China Threat Frames Everything Bourla's most pointed strategic warning: Chinese pharma is operating at **"half the cost and 3x the speed"** of Pfizer, Lilly, AstraZeneca, and Novo Nordisk. He gave Pfizer **a 5-year window** to transform competitively, drawing explicit comparison to China's takeover of EVs, solar, and batteries. AI is being positioned as the **primary lever** to close that cost/speed gap, with 3,000–4,000 employees now in tiered AI training programs. ### 5. AI as the Productivity Story Bourla called **Paxlovid** *"the first machine learning molecule that had such an impact"*, and signaled AI is now embedded across R&D with a decentralized operating model (center provides infrastructure, BUs own use cases). ### 6. Pricing Environment Bourla claimed drug-pricing pressure drove **2025 to "the lowest multiple in the history of the industry"** and the worst biotech funding environment on record (his framing, directionally consistent with broader sector commentary). --- ## 📰 Cross-Reference: This Week's News Tying Back to the Podcast Bourla's pipeline commentary lines up with two material PFE news items this week, context investors should weave together: **Pneumococcal franchise momentum:** Pfizer said on May 20 that its experimental 25-valent pneumococcal vaccine generated stronger immune responses than the company's currently approved PREVNAR 20 in a mid-stage infant study. Preliminary Phase 2 data showed antibody levels against serotype 3, a major remaining cause of pneumococcal disease in children, were significantly higher in infants receiving the investigational candidate, 25vPnC, compared with Prevnar 20 after both the third and fourth doses. The candidate could potentially cover up to 90% of disease-causing pneumococcal serotypes in children under five, and Pfizer has already started a pivotal pediatric Phase 3 trial enrolling up to 2,400 healthy children. Pfizer also plans to move directly to a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, expected to enter clinical development by end of 2026. This is exactly the kind of R&D productivity story Bourla was selling on the podcast, a tangible data point supporting his "Phase 2 success rate 50%+" claim. **ASCO 2026 watch:** Citizens biotech analysts are hosting a Key Opinion Leader dinner meeting at ASCO on May 29 to discuss novel therapeutics for breast cancer, with PFE flagged alongside CELC, RLAY, ARVN, ZYME, GILD, LLY, AZN, and NVS. Pfizer's breast cancer / ADC positioning (Seagen-derived assets) will be in focus, directly tied to Bourla's "overwhelming victory" Seagen narrative. --- ## 🎯 What to Watch Next Week 1. **ASCO 2026 (May 29 onwards)**, Pfizer's Seagen-derived ADC data will either reinforce or undercut Bourla's "overwhelming victory" framing. 2. **Sell-side reaction to 25vPnC Phase 2**, Watch for Raffat (Evercore) and Shibutani (Goldman) commentary. 3. **Medsara Phase 3 timeline disclosures**, The monthly-dosing oral obesity asset is Pfizer's single biggest swing factor vs. Lilly/Novo. --- ## ⚠️ Editor's Note on Source Quality This week's podcast coverage is **CEO-only**. There were no independent analyst, journalist, or buy-side voices on PFE in the May 20–24 window. Treat all claimed metrics (success rates, "exceptional" 2024–25 performance, China cost/speed benchmarks) as management commentary requiring independent verification. --- **Sources:** - [In Good Company with Nicolai Tangen, Albert Bourla interview (May 2026)](https://app.matterfact.com/podcasts/3eecff43a2ff44e60d20138ddff2806ff3b6594aa5643d93e7517ab5f1718084) - Pfizer Press Release / MT Newswires: "Pfizer Says Next-Generation Pneumococcal Vaccine Showed Stronger Immune Response in Infant Study" (May 20, 2026) - Citizens Biotech Analyst Note: ASCO KOL Dinner Meeting (May 22, 2026) --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` --- ```request-access heading: Run your own corpus. description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage. buttonText: Request access ```